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Abstract
Non-adherence to cardiovascular medications such as statins is a common, important problem.
Clinicians currently rely on intuition to identify medication non-adherence. The visit-to-visit
variability (VVV) of LDL-C may represent an opportunity to identify statin non-adherence with
greater accuracy. We examined the clinical and pharmacy data from 782 members of the Boston
Medical Center (BMC) Health Plan, seen at either BMC or its affiliated Community Health
Centers, who were taking statins and had at least 3 LDL-C measurements between 2008 and 2011.
The LDL-C VVV (defined by the within-patient standard deviation) was categorized into
quintiles. Multivariable logistic regression models were generated with statin non-adherence
(defined by the standard 80% pharmacy refill based medication possession ratio threshold) as the
dependent variable. The proportion of statin non-adherence increased across quintiles of LDL-C
VVV (64.3%, 71.2%, 89.2%, 92.3%, 91.7%). Higher quintiles of LDL-C VVV had a strong
positive association with statin non-adherence with an adjusted odds ratio of 3.4 (CI: 1.7–7.1) in
the highest versus lowest quintile of LDL-C VVV. The age and gender adjusted model had poor
discrimination [C-statistic 0.62 (CI: 0.57, 0.67)] while the final adjusted (age, gender, race, mean
LDL-C) model demonstrated good discrimination [C-statistic 0.75 (CI: 0.71, 0.79)] between
adherent and non-adherent patients. In conclusion, the VVV of LDL-C demonstrated a strong
association with statin non-adherence in a clinic setting. Further, a VVV- of LDL-C based model
has good discrimination characteristics for statin non-adherence. Research is needed to validate
and generalize these findings to other populations and biomarkers.
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The visit-to-visit variability (VVV) of cardiovascular risk factors, such as low-density
lipoprotein cholesterol (LDL-C), in clinical practice has been thought to be due to random
variation or measurement error.1–4 While there are several physiological mechanisms
posited to contribute to VVV, medication non-adherence may be a key contributor. 17
Indirect evidence for an effect of non-adherence on VVV comes from a meta-analysis of the
effect of different blood pressure medications on VVV which found that diuretics and
calcium channel blockers were associated with lower VVV than ACE inhibitors and beta-
blockers.5 18 This observation was thought to possibly be due to medication adherence,
although few data have tested this hypothesis.617 These observations create the possibility
that the VVV of a biomarker like LDL-C, which has a strong correlation to a medication
effect such as from statins, may demonstrate an observable phenomenon of VVV based on
differences in statin adherence. If established, the VVV of LDL-C could be used to detect
and trigger interventions to address statin non-adherence in clinical settings where pharmacy
claims data are not electronically integrated, as is currently the case in the large majority of
the US. To test this hypothesis, we conducted analyses using an integrated pharmacy claims
and clinical database from a large urban population of adult medical patients to determine
the independent association of VVV in LDL-C and statin adherence.
Methods
The study sample was patients enrolled in the Boston Medical Center Health Plan (BMCHP)
during years 2008 – 2011 who received care from Boston Medical Center (BMC) or any of
8 affiliated Community Health Centers during that time. The patient data were drawn from
the Massachusetts Health Disparities Repository (MHDR), which uses the Informatics for
Integrating Biology & the Bedside (i2b2) system to aggregate de-identified data for BMC
and BMCHP. The MDHR currently contains over 650 million EHR-based data elements
(medications, diagnoses, labs, visit dates, and clinical observations) as well as claims data
(including filled prescriptions) from the BMCHP for the over 1,200,000 individuals who
received at least one clinical service at BMC or any of 8 affiliated Community Health
Centers during the past 10 years. We utilized i2b2 to access data from the MHDR to
examine 74,468 BMCHP members seen at BMC during the sample period. From this group,
we limited our analysis to the 2,641 patients taking statin medications between 2008 and
2011. Of those taking statins during this time period, 1,886 had three or more fills; of those
with three or more statin prescriptions filled, 782 had three or more LDL-C measurements
between their first and last statin fulfillment dates (see Figure 1). LDL-C measurements that
fell outside the 0.1th and 99.9th percentiles were top and bottom coded to those values. If
multiple LDL-C measures existed for the same date (n=68 dates) then an average of the
same day measurements were used as part of the VVV estimation and it was counted only
once towards the three measure minimum. The primary exposure variable was the VVV of
LDL-C between the first and last statin fulfillment dates over the three year study period.
The VVV of LDL-C was defined as within-patient standard deviation over the study period.
LDL-C VVV was categorized into quintiles. The within-patient mean LDL-C was calculated
by averaging LDL-C measures over the study period.
The primary outcome is medication adherence to statins as determined from the medication
possession ratio (MPR). The MPR, also known as the proportion of days covered, is
calculated as the sum of days’ supply of the medication (in this case statin) obtained
between the first fill and the last fill divided by the total number of days in this time
period.7 19 This method was used as the main measure of medication adherence. The MPR
was calculated using all statin fills during the study period. Statin MPR was dichotomized as
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non-adherent and adherent according to the standard cutoff of <80% and >= 80%,
respectively.88
Covariate data of previously reported weak correlates of statin adherence were obtained
from the MHDR i2b2 portal and included: age at first statin fill during the study period; sex;
race/ethnicity (White, Black, Hispanic, Other); total number of outpatient visits during the
study period; mean LDL-C; number of LDL-C measurements during the study period;
number of days between first and last statin fills; and diagnosis of diabetes mellitus (ICD-9
codes 250.0× – 250.9×), ischemic heart disease (410.0× – 414.9×), hypertension (401.0× –
405.0×), chronic liver disease (571.0× – 571.9×), or cerebrovascular disease (430.0× –
438.9×) any time during the study period.9
Descriptive data are reported as percentages or means with standard deviations as
appropriate. All variables were examined for normality and outliers. Bivariate associations
between covariates and quintiles of LDL-C VVV, and between covariates and statin
adherence, were tested through chi-square statistics for categorical variables, and the
Wilcoxon rank-sum test for continuous variables.
Multivariable logistic regression models were used to examine the association between
VVV of LDL-C and statin non-adherence (MPR <80%). We performed an unadjusted model
with VVV of LDL-C alone, and an adjusted model including age at first statin fill, sex, race/
ethnicity (define above), and within-patient mean LDL-C. Additional covariates were
examined for inclusion in models but were not included as they did not materially affect the
results (number of LDL-C measurements during the study period; diagnoses of diabetes
mellitus, ischemic heart disease, hypertension, chronic liver disease, cerebrovascular disease
any time during the study period). For all logistic regression models, odds ratios (ORs) and
95% confidence intervals (CI) were calculated. The significance level was set at P-value
<0.05. The performance of each model for predicting statin MPR of <80% was assessed by
plotting the ROC curve and calculating the C-statistic (area under the ROC curve).
Sensitivity analyses were conducted by dichotomizing the VVV of LDL-C quintiles into the
1st and 2nd quintiles vs. the 3rd through 5th quintiles. We also substituted quintiles of VVV
of total cholesterol for quintiles of VVV of LDL-C and we dichotomized statin MPR as
<50% vs. 50% or higher. We also conducted analyses restricted to the 1st three LDL-C
measures to examine the impact of patients with larger numbers of LDL-C measures. We
also conducted an analysis dropping the first LDL-C measure as an indirect control for the
effect of a “first statin fill” effect in which there should be a substantial variation between
LDL-C measures; an effect that might dilute the relationship of adherence and LDL-C VVV.
We also repeated all analyses using coefficient of variation (CV) instead of standard
deviation as the measure of VVV and using a continuous measure of LDL-C VVV. Data
analyses were conducted using SAS/STAT software, Version 9.2 of the SAS System for
Windows (2002–2008,SAS Institute Inc., Cary, NC, USA).
Results
After restricting the dataset to patients with at least three statin pharmacy claims and three
LDL-C values within the dates of the first and last statin fill, the final analytic dataset
contained 782 patients. The average within-patient mean LDL-C for our sample was 109.2
(SD±32.9) mg/dL.
The VVV of LDL-C ranged from 0.6 to 79.6, with mean 21.7 (SD ± 13.1). There was equal
distribution by sex, race, number of outpatient visits and days between first and last statin
fills across VVV quintiles (Table 1). Mean age at first statin fill declined as the quintile of
VVV increased with a more significant decline with increasing VVV quintile when age was
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dichotomized at 55 years (data not shown). The proportion of the sample with diabetes also
significantly declined as the quintile of VVV increased. The number of LDL-C
measurements [mean=4.6 (SD ± 1.8)] and the within patient mean LDL-C level both
significantly increased with increasing LDL-C VVV.
There was no significant association between statin non-adherence and gender, number of
outpatient visits, comorbidities, number of LDL measurements or number of days between
first and last statin fills (Table 2). Younger age was associated with statin non-adherence.
Race also demonstrated a significant relationship with statin non-adherence with Blacks
having a higher proportion of statin non-adherence as compared to all other race groups.
Higher within-patient mean LDL was significantly associated with statin non-adherence.
The prevalence of statin non-adherence increased across higher quintiles of LDL-C VVV
(64.3%, 71.2%, 89.2%, 92.3%, 91.7%). In unadjusted logistic regression models, a strong
positive and significant association was noted between increasing quintiles of VVV and
statin non-adherence (Table 3). When adjusted for gender, age at first statin fill, race, and
within-patient mean LDL-C, the association was attenuated but remained statistically
significant. Inclusion of the number of LDL-C measurements, number of outpatient visits,
number of days between first and last statin fills, or comorbidities to the model did not
appreciably change the association of VVV of LDL-C and adherence (data not shown).
Figure 2 depicts the ROC curves for discrimination between adherence and non-adherent
patients between four models: 1) age and sex (C-statistic 0.62, CI: 0.57, 0.67); 2) age, sex,
race and mean LDL-C (C-statistic 0.70, CI: 0.65, 0.74); 3) age, sex, race, and VVV of LDL-
C (C-statistic 0.75, CI: 0.70, 0.79); and 4) age, sex, race, mean LDL-C and VVV of LDL-C
(C-statistic 0.75, CI: 0.71, 0.79).
The logistic regression results were similar when VVV of total cholesterol was used in place
of LDL-C (data not shown). Dichotomizing statin MPR at <50% and 50% or higher also did
not change the results. Collapsing of the VVV quintiles into two groups that appeared to
cluster (quintiles 1–2 versus quintiles 3–5) led to no change in results, with the upper
quintiles showing odds about four times higher for statin non-adherence in unadjusted and
adjusted models in comparison to lower quintiles (data not shown). Mean LDL-C divided
into quintiles was not a significant correlate of non-adherence (p=.16) with odds ratios of 1.3
(0.7–2.2), 1.4 (0.7–2.6), 1.2 (0.6–2.2), and 2.7 (1.2–5.9) across increasing quintiles.
Restricting analyses to only the first 3 LDL measures to remove any potential confounding
from outliers with many LDL-C measures provided similar results (Supplement Table 1).
Analyses with the 1st LDL-C measure dropped for each patient also found similar, if not
stronger, findings (Supplement Table 2). There were no significant interactions between
mean LDL-C and VVV and analyses using coefficient of variation instead of standard
deviation as the measure of VVV were similar (Supplement Table 3 and Supplement Figure
1). Analyses using VVV of LDL-C as a continuous measure are presented in Supplement
Table 4).
Discussion
These data show a positive association between increasing VVV of LDL-C and statin non-
adherence, measured using pharmacy refill data. The relationship was maintained in
adjusted models that incorporated key covariates that have traditionally been associated with
non-adherence, including mean within patient LDL-C and number of LDL-C measurements.
The magnitude of the relationship was substantial, with the adjusted odds of being non-
adherent to statins near four in the higher quintiles of VVV. The ROC curve including VVV
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demonstrated good adherence discrimination characteristics – creating the potential that a
VVV based prediction model may be useful in identifying statin non-adherence.
Approaches used to identify medication non-adherence include self-report, pill counts,
pharmacy records, and electronic medication event monitoring systems.88 Pill counts and
electronic monitoring systems commonly fail and are too costly and burdensome for use in
routine clinical settings.8 Self-reported questionnaires, while simple, have poor reliability
and are difficult to administer in busy clinical settings.8 Databases in which clinical and
pharmacy data are linked allow for generation of objective medication adherence estimates
and are frequently used by researchers.109 However, this metric is unavailable in most US
healthcare systems due to the lack of integration between clinical and pharmacy claims data
systems, particularly those serving disadvantaged and minority populations in whom non-
adherence is both common and associated with morbidity.11 There is a great need for real-
time, point-of-care tools for helping clinicians improve their ability to identify and intervene
on non-adherent patients.
The observed relationship between VVV of LDL-C and statin non-adherence has the
potential to be just such a tool as it has a relationship to non-adherence substantially stronger
than previously identified correlates. In a prior meta-analysis of 22 cohort studies, the
significant markers of statin non-adherence (age, gender, income, history of cardiovascular
disease, diabetes, hypertension) all demonstrated relatively modest relationships with peak
odds ratios of about 30%.94 As a result, prior clinical and socio-demographic variables are
not likely to be useful markers of medication non-adherence.1212 The VVV of LDL-C is a
novel method to transform clinical data into a useful marker of statin adherence. To our
knowledge, this has not been previously exhibited.
The substantial discrimination ability of VVV in combination with the other significant
variables represents a potentially important finding. We began our model building with the
variables previously identified as associated with statin adherence in the prior literature. The
covariates included in our final model have previously been identified as weak markers of
statin adherence but have never been successfully used to discriminate between adherence
and non-adherence.9,13,14 We then added VVV to the model, which was the most significant
variable included. For the first time we created a prediction model with a strong association
with statin adherence.
There is a compelling clinical rationale for why the VVV of LDL-C appears to have a strong
relationship to statin adherence. Statins, particularly newer generic statins such as
simvastatin, have a potent effect on mean LDL-C. As such, non-adherence to these drugs
will likely have a relatively dramatic effect on mean LDL-C. Underlying drivers of non-
adherence such as concerns about side-effects, doubts about the need for drug therapy,
problems with costs and other psychosocial variables are difficult to detect in a busy clinical
setting.13,15 Since VVV likely incorporates the impact of these variables in addition to other
more modest epidemiologic variables, this may explain the more substantial relationship.
Moreover, VVV of LDL-C could easily be computed at the point-of-care in a modern
electronic health record making it a potentially powerful and scalable non-adherence
screening strategy. With the ability to more reliably screen for statin non-adherence,
clinicians may be able to avoid unnecessary dose titration in patients who are non-adherence
and target these patients with specific adherence interventions.16
Our findings were robust to several sensitivity analyses. Using total cholesterol instead of
LDL-C and changing the adherence thresholds from 80% to 50% did not alter the results.
Altering the categorization of the VVV grouping from quintiles into 2 categories also did
not alter the findings; this further strengthens the validity of the observed association.
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The study findings need to be viewed within the context of several limitations. First, the
dataset applies to a large, urban medical cohort with a disproportionate number of minorities
and a high percentage of Medicaid enrollees. Future studies will need to replicate these
findings in other datasets to ensure their validity and generalizability to other populations.
However, Massachusetts health reform which was enacted before 2008 helps minimize the
impact of cost on non-adherence in the sample. The study sample was also limited to those
enrolled in a specific Medicaid health insurance plan which represents another limitation to
the generalizability of the findings but is difficult to predict in what direction this could bias
the data. The use of pharmacy claims to assess medication adherence is a standard practice,
but does suffer from issues of patient pill dumping or storing medications and does not take
into account nor differentiate between patient versus physician directed discontinuation.
Therefore there is likely some misclassification of the exposure which would bias our results
to the null. Furthermore, as this is a clinical database, the LDL-C sample cannot be verified
as fasting which may reduce the accuracy of the LDL-C estimates. The sample also had a
high prevalence of diabetes and hypertension which is likely due to the lower threshold for
use of statins in these populations and the need for frequent visits among both groups which
gives greater opportunity for LDL-C measures. We used quintiles of VVV as there are no
published clinically relevant cut-points for VVV of LDL-C. These limitations are
counterbalanced by several study strengths including the use of a practice based clinical
sample that incorporates a population that is disproportionately affected by cardiovascular
disease and non-adherence.17
Next steps for this research include analyses to identify optimal thresholds of VVV to detect
statin non-adherence. Fortunately, as the intervention for non-adherence is very low risk
(often enhanced counseling), the sensitivity can, in theory, be maximized in favor of
specificity. These relationships must also been validated in other datasets with different
clinical populations and potential interactions with other medications examined. The impact
of whether patients are currently at goal for statin therapy or not also needs to be examined
in future studies. The relationship between VVV of other cardiovascular biomarkers such as
hemoglobin A1C and SBP also needs to be examined to determine if the observed
relationship with VVV of LDL-C, if validated, is a unique phenomenon of statins or is an
example of a more robust association between the variability in cardiovascular biomarkers
and medication adherence. More work is also needed to identify the number of LDL-C
measurements needed to get a reproducible estimate of VVV and to maximize its non-
adherence discrimination ability.
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Flow diagram of study inclusion criteria
Mann et al. Page 8














Sequential ROC curves for identification of statin adherence (defined as statin MPR <80%
vs. 80%+) using age, sex, race, mean LDL-C, and VVV of LDL-C with final model c-
statistic 0.75 (CI: 0.71, 0.79).
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Table 2









Female 353 (55%) 73 (51%) 426 (55%) 0.36
Male 286 (45%) 70 (49%) 356 (46)
Age at 1st Rx Fill
Mean (SD) 52 (8) 55 (7) 53 (8) <0.01
White 135 (21%) 50 (36%) 185 (24%) <0.01
Black 258 (41%) 42 (30%) 300 (39%)
Hispanic 122 (19%) 18 (13%) 140 (18%)
Other 118 (19%) 31 (22%) 149 (19%)
Number of outpatient visits
Mean (SD) 45 (41) 47 (44) 46 (42) 0.96
Diagnoses
Diabetes mellitus 422 (66%) 90 (63%) 512 (66%) 0.48
Ischemic heart disease 137 (21%) 31 (22%) 168 (22%) 0.95
Hypertension 568 (89%) 130 (91%) 698 (89%) 0.48
Chronic liver disease 33 (5%) 10 (7%) 43 (6%) 0.39
Cerebrovascular disease 62 (10%) 14 (10%) 76 (10%) 0.97
Framingham risk index




4.6 (1.8) 4.5 (1.8) 4.6 (1.8 0.36
Within patient mean LDL
Mean (SD) 112 (33) 96 (29) 109 (33) <0.01
Number of days between
1st and last fill dates
Mean (SD)
1000 (338) 968 (418) 994 (354) 0.97
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Table 3
Logistic regression models predicting the odds of statin MPR <80%, quintiles of within-patient standard
deviation (SD) of LDL Subjects with at least 3 statin fills and at least 3 LDL measurements within dates of
first/last statin fill
Unadjusted*
OR (95% CI) p-value
Adjusted**
OR (95% CI) p-value
VVV (LDL SD quintiles)
1st quintile (ref) 1.00 (−) <0.0001 1.00 (−) <0.0001
2nd quintile 1.37 (0.85, 2.20) 1.12 (0.68, 1.85)
3rd quintile 4.57 (2.51, 8.32) 3.44 (1.83, 6.46)
4th quintile 6.61 (3.37, 12.95) 4.47 (2.19, 9.10)
5th quintile 6.14 (3.19, 11.82) 3.43 (1.65, 7.14)
Age at 1st statin fill (1 year increase) 0.96 (0.94, 0.99) 0.01
Sex 1.00 (−) 0.76
Female (ref) 0.94 (0.63, 1.40)
Male
Race 0.95 (0.51, 1.77) 0.01
Hispanic 0.68 (0.39, 1.17)
Other 0.46 (0.28, 0.75)
White 1.00 (−)
Black (ref)
Within-patient mean 1.01 (1.00, 1.02) 0.01
LDL
*
Hosmer and Lemeshow Goodness-of-Fit Test p-value 1.000
**
Hosmer and Lemeshow Goodness-of-Fit Test p-value 0.3129
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